Latest News

Early cystoscopy after Bacillus Calmette–Guérin (BCG) induction is essential and plays an important role in ensuring to recognize BCG refractory tumors. Although Photodynamic diagnosis cystoscopy (PDD-C) is proven to be more sensitive than white light cystoscopy (WL-C) particularly for CIS,1 there is currently no recommendation to use PDD for surveillance. WL-C is the gold standard […]

The terms Disparities and Inequities are used almost interchangeably in Health Services Research. Specifically, well-established health disparities exist both in diagnostic imaging utilization and in prostate cancer (PCa) outcomes. In fact, African Americans (AAs) suffer PCa with almost twice the incidence and mortality compared to Non-Hispanic Whites (NHW). What is often overlooked in the current […]

The optimal length for clinical follow-up of renal cell carcinoma (RCC) patients is unclear. We evaluated the impact of ISUP/WHO tumor grade and histological subtype on short- and long-term survival and risk of recurrence/metastasis in a large cohort of RCC patients.

We performed subgroup analyses of the AFTER I-O study to clarify the association of time-to-treatment failure (TTF) and discontinuation reason of prior immune-oncology (I-O) therapy, and molecular targeted therapy (TT) regimen with the outcomes of TT after I-O.

Radical surgery is the first line treatment for localized prostate cancer (PC), however, several studies have demonstrated that surgical procedures induce tumor cell mobilization from the primary tumor into the bloodstream.

The COVID-19 pandemic dramatically impacted society and health care on a global scale. To capture the lived experience of patients with prostate cancer and family members/caregivers during the COVID-19 pandemic, we performed a mixed-methods study of posts to two online networks.

Although fear of cancer recurrence (FCR) or disease progression is among the most endorsed unmet needs and concerns of cancer survivors, research on the course of FCR in long-term survivors is scarce.

To assess the whole pathology spectrum of PI-RADS 3 MRI lesions using systematic (SB), targeted biopsy (TB), and radical prostatectomy (RP) specimens’ analysis. From a prospective database of patients undergoing RP after a combination of SB (median 12 cores) and fusion TB (median 3 cores), we included 150 PI-RADS 3 cases.

Prostate cancer (PCa) diagnostic and therapeutic work-up has evolved significantly in the last decade, with pre-biopsy multiparametric MRI now widely endorsed within international guidelines. There is potential to move away from the widespread use of systematic biopsy cores and towards an individualised risk-stratified approach.